Abstract
BackgroundHigh-altitude cerebral edema (HACE) is the severe type of acute mountain sickness (AMS) and life threatening. A subclinical inflammation has been speculated, but the exact mechanisms underlying the HACE are not fully understood.MethodsHuman volunteers ascended to high altitude (3860 m, 2 days), and rats were exposed to hypoxia in a hypobaric chamber (5000 m, 2 days). Human acute mountain sickness was evaluated by the Lake Louise Score (LLS), and plasma corticotrophin-releasing hormone (CRH) and cytokines TNF-α, IL-1β, and IL-6 were measured in rats and humans. Subsequently, rats were pre-treated with lipopolysaccharide (LPS, intraperitoneal (ip) 4 mg/kg, 11 h) to induce inflammation prior to 1 h hypoxia (7000 m elevation). TNF-α, IL-1β, IL-6, nitric oxide (NO), CRH, and aquaporin-4 (AQP4) and their gene expression, Evans blue, Na+-K+-ATPase activity, p65 translocation, and cell swelling were measured in brain by ELISA, Western blotting, Q-PCR, RT-PCR, immunohistochemistry, and transmission electron micrography. MAPKs, NF-κB pathway, and water permeability of primary astrocytes were demonstrated. All measurements were performed with or without LPS challenge. The release of NO, TNF-α, and IL-6 in cultured primary microglia by CRH stimulation with or without PDTC (NF-κB inhibitor) or CP154,526 (CRHR1 antagonist) were measured.ResultsHypobaric hypoxia enhanced plasma TNF-α, IL-1β, and IL-6 and CRH levels in human and rats, which positively correlated with AMS. A single LPS injection (ip, 4 mg/kg, 12 h) into rats increased TNF-α and IL-1β levels in the serum and cortex, and AQP4 and AQP4 mRNA expression in cortex and astrocytes, and astrocyte water permeability but did not cause brain edema. However, LPS treatment 11 h prior to 1 h hypoxia (elevation, 7000 m) challenge caused cerebral edema, which was associated with activation of NF-κB and MAPKs, hypoxia-reduced Na+-K+-ATPase activity and blood-brain barrier (BBB) disruption. Both LPS and CRH stimulated TNF-α, IL-6, and NO release in cultured rat microglia via NF-κB and cAMP/PKA.ConclusionsPreexisting systemic inflammation plus a short severe hypoxia elicits cerebral edema through upregulated AQP4 and water permeability by TLR4 and CRH/CRHR1 signaling. This study revealed that both infection and hypoxia can cause inflammatory response in the brain. Systemic inflammation can facilitate onset of hypoxic cerebral edema through interaction of astrocyte and microglia by activation of TLR4 and CRH/CRHR1 signaling. Anti-inflammatory agents and CRHR1 antagonist may be useful for prevention and treatment of AMS and HACE.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-016-0528-4) contains supplementary material, which is available to authorized users.
Highlights
High-altitude cerebral edema (HACE) is the severe type of acute mountain sickness (AMS) and life threatening
Exposure of rats to hypobaric hypoxia (10.8 % O2, at altitude of ~5000 m) for 2 days increased plasma levels of corticotrophin-releasing hormone (CRH), TNF-α, IL-1β (Fig. 1g–i), and hypoxia (7000 m, 8 h)-increased plasma levels of TNF-α and IL-1β were blocked by corticotrophin-releasing hormone receptor type 1 (CRHR1) antagonist (CP154,526) (Fig. 1j, k), suggesting that hypobaric hypoxia induces an immune-inflammatory response in humans and rats, which is positively associated with activation of CRH/CRHR1 and with the development of AMS in humans
The present study shows that in humans and rats, hypobaric hypoxia causes an inflammatory response with cytokine release, which positively correlates to severity of AMS syndrome in humans and with activation of CRHR1 in central microglia and peripheral tissues in rats
Summary
High-altitude cerebral edema (HACE) is the severe type of acute mountain sickness (AMS) and life threatening. Studies of the physiology and pathophysiology of the blood-brain barrier (BBB) show that brain edema occurs consequent to astrocyte swelling and increase in BBB permeability [7] In hypobaric hypoxia, these latter pathological effects depend on upregulation of aquaporin-4 (AQP4) in astrocytes via activation of corticotrophin-releasing hormone receptor type 1 (CRHR1) following increased local secretion of corticotrophin-releasing hormone (CRH) in the brain [8]. These latter pathological effects depend on upregulation of aquaporin-4 (AQP4) in astrocytes via activation of corticotrophin-releasing hormone receptor type 1 (CRHR1) following increased local secretion of corticotrophin-releasing hormone (CRH) in the brain [8] This accords with several studies showing a critical role of upregulated-AQP4 in the formation of brain edema in various pathological clinical conditions including ischemia and trauma [9, 10]. Why and how these changes may progress at high altitude to more severe AMS and HACE is unclear
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.